This article has been updated to include information from Myriad's 10-Q filing and stock pricing information.

NEW YORK (GenomeWeb) – Myriad Genetics reported after the close of the market on Tuesday that its first quarter revenues in fiscal 2017 fell 3 percent, thanks in part to an 11 percent drop in hereditary cancer testing revenues.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.